Hui Zhu

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Tyrosine Kinase

Prognostic Factors

Brain Metastases

Radiation Induced

Top Venues

Cancer medicine

Journal of translational medicine

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Runze Liu, Guangjian Yang, Hongbo Guo, Feihu Chen, Shuangqing Lu, Hui Zhu
Roles of naïve CD4 + T cells and their differentiated subtypes in lung adenocarcinoma and underlying potential regulatory pathways. Journal of translational medicine 22 (1) (2024)
Shuangqing Lu, Xiaokang Guo, Zhengqiang Yang, Yulan Sun, Jiling Niu, Xuquan Jing, Hui Zhu
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study. Future oncology (London, England) (2024)
Shuangqing Lu, Xiaokang Guo, Zhengqiang Yang, Yulan Sun, Jiling Niu, Xuquan Jing, Hui Zhu
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study. Future oncology (London, England) (2024)
Jiling Niu, Xuquan Jing, Qinhao Xu, Haoyu Liu, Yaru Tian, Zhengqiang Yang, Hui Zhu, Yulan Sun
Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs. Future oncology (London, England) (2024)
Runze Liu, Guangjian Yang, Hongbo Guo, Feihu Chen, Shuangqing Lu, Hui Zhu
Roles of naïve CD4 + T cells and their differentiated subtypes in lung adenocarcinoma and underlying potential regulatory pathways. Journal of translational medicine 22 (1) (2024)
Runze Liu, Guangjian Yang, Hongbo Guo, Feihu Chen, Shuangqing Lu, Hui Zhu
Roles of naïve CD4 + T cells and their differentiated subtypes in lung adenocarcinoma and underlying potential regulatory pathways. Journal of translational medicine 22 (1) (2024)
Feihu Chen, Jiling Niu, Min Wang, Hui Zhu, Zhijun Guo
Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy. Journal of translational medicine 21 (1) (2023)
Shuangqing Lu, Xiaokang Guo, Yuying Li, Haoyu Liu, Yan Zhang, Hui Zhu
Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis. Cancer (2023)
Min Wang, Ji Li, Shuhui Xu, Yuying Li, Jiatong Li, Jinming Yu, Xiaoyong Tang, Hui Zhu
Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients. Cancer medicine (2022)
Yaru Tian, Xiaoyang Zhai, Weiwei Yan, Hui Zhu, Jin-Ming Yu
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer medicine 10 (1) (2020)
Yang Liu, Yinping Dong, Hui Zhu, Wang Jing, Hongbo Guo, Jin-Ming Yu
Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study. Cancer medicine 9 (4) (2019)
Weiwei Yan, Wang Jing, Ning An, Yaru Tian, Dong Guo, Li Kong, Hui Zhu, Jin-Ming Yu
The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute. Cancer medicine 8 (6) (2019)
Ning An, Wang Jing, Haoyi Wang, Ji Li, Yang Liu, Jinming Yu, Hui Zhu
Risk factors for brain metastases in patients with non-small-cell lung cancer. Cancer medicine 7 (12) (2018)